Summary
3.66 0.04(1.11%)03/13/2026
Sight Sciences, Inc. (SGHT)
SGHT reported last earnings on 2026-03-04 after the market. An EPS of $-0.07841 was observed compared to an estimated EPS of $-0.15, resulting in a surprise value of $0.07. A revenue of $20 million was observed compared to an estimated revenue of $19 million, resulting in a surprise value of $1 Million.
Sight Sciences, Inc. (SGHT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.10 | 20.33 | 54.55 | 88.89 | 132.27 | 100.75 | -76.15 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 3.66 | |
| Open | 3.57 | |
| High | 3.76 | |
| Low | 3.57 | |
| Volume | 236,905 | |
| Change | 0.04 | |
| Change % | 1.10 | |
| Avg Volume (20 Days) | 238,134 | |
| Volume/Avg Volume (20 Days) Ratio | 0.99 | |
| 52 Week Range | 2.05 - 8.23 | |
| Price vs 52 Week High | -55.53% | |
| Price vs 52 Week Low | 78.54% | |
| Range | 0.00 | |
| Gap Up/Down | -0.20 | |
Profitibility | ||
| Market Capitalization (Mln) | 333 | |
| Revenue per share | 1.4574 | |
| Net Income per share | -0.7239 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -5.0698 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/06 14:13 EST - globenewswire.com
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whether investor losses may be recovered under federal securities...
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whether investor losses may be recovered under federal securities...
03/04 19:02 EST - seekingalpha.com
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
03/04 19:01 EST - zacks.com
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
03/04 18:16 EST - zacks.com
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
03/04 16:05 EST - globenewswire.com
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives,...
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives,...
02/25 11:01 EST - zacks.com
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/18 16:05 EST - globenewswire.com
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
01/21 03:27 EST - defenseworld.net
Americana Partners LLC Grows Stock Holdings in Sight Sciences, Inc. $SGHT
Americana Partners LLC boosted its stake in shares of Sight Sciences, Inc. (NASDAQ: SGHT) by 42.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,229,819 shares of the company's stock after buying an...
Americana Partners LLC Grows Stock Holdings in Sight Sciences, Inc. $SGHT
Americana Partners LLC boosted its stake in shares of Sight Sciences, Inc. (NASDAQ: SGHT) by 42.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,229,819 shares of the company's stock after buying an...
01/13 07:05 EST - globenewswire.com
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
12/31 11:29 EST - seekingalpha.com
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a...
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a...
12/18 13:01 EST - zacks.com
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
11/11 13:01 EST - zacks.com
Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know
Sight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know
Sight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
11/06 22:16 EST - seekingalpha.com
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Sight Sciences, Inc. ( SGHT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Badawi - Co-Founder, President, CEO & Director Jim Rodberg - VP of Finance & Corporate Controller Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Conference Call...
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Sight Sciences, Inc. ( SGHT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Badawi - Co-Founder, President, CEO & Director Jim Rodberg - VP of Finance & Corporate Controller Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Conference Call...
11/06 20:31 EST - zacks.com
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
11/06 19:55 EST - zacks.com
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago.
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago.
11/06 16:05 EST - globenewswire.com
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
11/06 16:04 EST - globenewswire.com
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable...
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable...
11/04 16:05 EST - globenewswire.com
Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
10/23 16:05 EST - globenewswire.com
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
10/17 07:00 EST - globenewswire.com
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Market News
×
Loading news…